NewsBenzingaBarclays mantiene la calificación de sobreponderar sobre Collegium Pharmaceutical y reduce el precio objetivo a 41 dólares Barclays mantiene la calificación de sobreponderar sobre Collegium Pharmaceutical y reduce el precio objetivo a 41 dólares Benzinga 2026.11.16 15:16 (GMT+0) Open on Benzinga Other news Tether-Backed Stablecoin USA₮ Goes Live on Avalanche Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts A Strong Q3 Puts Nvidia (NVDA) Stock on Track for a Quick 194% Options Payout As Netflix Stock Hovers Near Its 52-Week Low, Analyst Sentiment Remains Mixed. Here's Why. How to Play General Motors Stock as GM Shares Switch to the Nasdaq British hackers face prison for GTA 6 data breach and crypto thefts
Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts